Indeed, some human cancers display elevated levels of cytoplasmic CDKN1A or cytoplasmic CDKN1B, which is associated with poor prognosis [35–38], and badly response to cisplatin based treatment [39, 40]. This evidence concerns the gene CDKN1B and cancer.